Journal of AdvancedMedical and Dental Sciences Research

Aim: To find out the effective treatment as an antiviral agent for COVID-19, to determine the correlation between sociodemography with clinical outcomes and duration of treatment, and to determine the relationship between comorbidities with clinical outcomes and duration of treatment for COVID-19 patients. Methods: A prospective cohort study was conducted in this study. This study included only confirmed COVID-19 patients who were admitted to the hospital during April-May 2020. Convenience sampling was used to select 100 patients, but only 60 patients were suitable for inclusion. Results: The survival analysis for COVID-19 patients using the Kaplan Meier method showed that patients receiving Oseltamivir + Hydroxychloroquine had an average survival rate of about 83% after undergoing treatment of about ten days. Gender (p = 0.550) and age (p = 0.280) did not have a significant correlation with the duration of treatment for COVID-19 patients. Conclusion: The most effective antiviral agent in this study based on treatment duration was the combination of Oseltamivir + Hydroxychloroquine. The higher the patient’s average treatment duration is, the lower the average survival rate for COVID-19 patients.